The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients

Lung Cancer

Volumn 61, Issue 1, 2008, Pages 67-72

  Gridelli, Cesare ^a   De Maio, Ermelinda ^b   Barbera, Santi ^c   Sannicolò, Mirella ^d   Piazza, Elena ^e   Piantedosi, FrancoVito ^f   Brancaccio, Luigi ^f   Morabito, Alessandro ^b   Maione, Paolo ^a   Renda, Francesco ^c   Signoriello, Giuseppe ^g   Perrone, Francesco ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Mariano Santo Hospital   (Italy)

^d Ospedale S Maria del Carmine   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f MONALDI HOSPITAL   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Elderly patients; Gemcitabine; NSCLC

Indexed keywords

GEMCITABINE;

ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAIR LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE;

EID: 45549085380     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.12.002     Document Type: Article

References (22)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. SEER Cancer Statistics review 1975-2004. http://www.seer.cancer.gov.
3. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
4. Furuse K. Gemcitabine in the treatment of non-small cell lung cancer for elderly patients. Gan To Kagaku Ryoho 26 (1999) 890-897
5. Ricci S., Antonuzzo A., Galli L., Tibaldi C., Bertuccelli M., Lopes Pegna A., et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A multicentre phase II study. Lung Cancer 27 (2000) 75-80
6. Altavilla G., Adamo V., Buemi B., Marabello G., Maisano R., Lupo G., et al. Gemcitabine as single agent in the treatment of elderly patients with advanced non-small cell lung cancer. Anticancer Res 20 (2000) 3675-3678
7. Martoni A., Di Fabio F., Guaraldi M., Piana E., Ramini R., Lelli G., et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol 24 (2001) 614-617
8. Bianco V., Rozzi A., Tonini G., Santini D., Magnolfi E., Vincenzi B., et al. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res 22 (2002) 3053-3056
9. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedisi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
10. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
11. Gridelli C., Aapro M., Ardizzoni A., Balducci L., De Marinis F., Kelly K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel. J Clin Oncol 23 (2005) 3125-3137
12. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J., Tarassoff P., and Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′. 2′-difluorodeoxycytidine (gemcitabine) administration in leukaemia. Cancer Res 50 (1990) 6823-6826
13. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
14. Grunewald R., Kantarjian H., Du M., Faucher K., Tarassoff P., and Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 10 (1992) 406-413
15. Tempero M., Plunkett W., Ruiz van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose intense gemcitabine: thirty-minute infusion and fixed dose rate infusion inpatients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
16. Gridelli C., Maione P., Illiano A., Piantedosi F.V., Favaretto A., Bearz A., et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small cell lung cancer: the MILES-2P studies. J Clin Oncol 25 (2007) 4663-4669
17. Ceribelli A., Gridelli C., De Marinis F., Fabi A., Gamucci T., Cortesi E., et al. Prolonged gemcitabine infusion in advanced non-small cell lung cancer carcinoma. Cancer 98 (2003) 337-343
18. Tibaldi C., Bernardini I., Chella A., Russo F., Toma G., Tempestini F., et al. Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. Lung Cancer 51 (2006) 217-223
19. Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G.V., Barbieri F., et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52 (2006) 319-325
20. Xu N., Shen P., Zhang X.C., Yu L.F., Bao H.Y., Shi G.M., et al. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 59 (2007) 1-7
21. Cattel L., Airoldi M., Delprino L., Passera R., Milla P., and Pedani F. Pharmacokinetic evaluation of gemcitabine and 2′. 2′-difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 17 (2006) v142-v147
22. Gridelli C., Gallo C., Ceribelli A., Gebbia V., Gamucci T., Ciardiello F., et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8 (2007) 500-512